与当前标准治疗相比,大麻素对多发性硬化症患者的症状缓解的有效性 (CANSEP试验):一项随机临床试验的研究协议
Amel Zertal1, Kanza Alami Marrouni1,2, Nathalie Arbour1,2
1Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Frontiers in neurology
|August 8, 2024
概括
这项临床试验调查了四大麻 (THC) 和大麻 (CBD) 对多发性硬化症 (MS) 症状缓解的有效性. 它旨在确定治疗性和其他MS相关疾病的最佳大麻素治疗方法.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 多发性硬化症 (MS) 是一种慢性,炎症性和退行性中枢神经系统疾病,影响着9万多名加拿大人.
- 目前的多发性硬化症治疗只能提供部分疗效,因此需要研究替代治疗方案.
- 大麻,包括四大麻 (THC) 和大麻 (CBD),被多发性硬化症 (PwMS) 患者用于症状管理,但科学证据有限.
研究的目的:
- 为了评估单独或联合使用的THC和CBD不同剂量的有效性,以减轻PwMS患者的性,与安慰剂相比.
- 确定最佳的大麻素治疗策略,以管理关键的多发性硬化症症状并改善患者的整体功能.
主要方法:
- 一个双盲,随机,因子,安慰剂控制的试验,涉及多达250名21岁以上的PwMS.
- 参与者将随机分配,接受单独的THC,单独的CBD,THC/CBD组合或安慰剂.
- 主要结局是通过数值评分尺度在7天内自我评估的性,与基线相比,在4周内测量. 二次结果包括临床医生评估的性,疼痛,疲劳,睡眠和生活质量.
主要成果:
- 在研究完成并获得结果后,该部分将被填写.
- 该研究旨在提供关于特定大麻素在MS症状管理中的疗效的定量数据.
- 分析的重点是将治疗臂与安慰剂进行比较,并确定症状减轻的显著差异.
结论:
- 该CANSEP研究旨在解决关于PwMS中特定大麻素的益处和风险的缺乏证据的问题.
- 这些发现将通过提供THC和CBD在治疗多发性硬化症症状中的有效性数据来告知临床实践.
- 这项研究预计将指导开发更有效的,基于证据的,基于大麻的多发性硬化症治疗策略.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
207
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
207
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
172
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
172
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Analgesia and Pain Management
555
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
555
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
109
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
109
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124


